The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1559
November 5, 2018
View Complete Issue         Table of Contents 2019 
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
November 5, 2018 (Issue: 1559)
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
Article code: 1559a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.